STOCK TITAN

Schedule 13D/A: Viking entities disclose 9.1%–9.7% holdings in BridgeBio (BBIO)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Amendment No. 8 to a Schedule 13D reports updated beneficial ownership information for the common stock of BridgeBio Pharma, Inc. ("Common Stock"). Multiple Viking-related entities and individuals are disclosed as reporting persons. Percentage calculations are based on 191,168,504 shares outstanding as of July 29, 2025. The cover pages show key positions: Viking Global Investors LP reports shared beneficial ownership of 17,780,183 shares (9.3%); Viking Global Opportunities-related entities report shared holdings of 17,489,651 shares (9.1%); and three individuals (O. Andreas Halvorsen, David C. Ott and Rose S. Shabet) are each reported with shared beneficial ownership of 18,602,920 shares (9.7%). The filing states the funds used were investor capital and incorporates a Schedule of Transactions as Exhibit 99.8. No transactions since Amendment No. 7 are reported except those listed in Exhibit 99.8.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Significant disclosed stakes by Viking-affiliated funds and principals approach 10%, a material ownership position to note.

The filing consolidates beneficial ownership across multiple Viking entities and identifies shared voting and dispositive power exercised through investment managers and general partners. Percentages are calculated on 191,168,504 outstanding shares, with key figures: 17,780,183 shares (9.3%) for Viking Global Investors LP and 18,602,920 shares (9.7%) for certain individuals. This scale of holdings is material for shareholder composition and could affect shareholder dynamics. The source of funds is investor capital and a transactions schedule is provided as Exhibit 99.8. The disclosure is procedural and updates prior Schedule 13D amendments without adding new narrative objectives.

TL;DR: Clear mapping of voting/dispositive authority among funds, managers and named executives clarifies who may influence corporate votes.

The amendment details which entities have authority to vote and dispose of shares and describes how VGI, VGP, VLFGP, Opportunities Portfolio GP and related managers may be deemed beneficial owners through their control relationships. It also confirms delegated signing authority for filings. These disclosures improve transparency about which parties hold shared control over substantial positions, which is important for board engagement and voting outcomes. The filing references Exhibit 99.8 for transaction detail and incorporates prior amendments.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
All share percentage calculations in this Amendment No. 8 to the Schedule 13D are based on 191,168,504 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of July 29, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on August 5, 2025.


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


VIKING GLOBAL INVESTORS LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
Date:08/14/2025
VIKING GLOBAL PERFORMANCE LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL PERFORMANCE LLC (1)(2)(3)
Date:08/14/2025
Viking Global Equities II LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Equities II LP (1)(2)(3)
Date:08/14/2025
Viking Global Equities Master Ltd.
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Equities Master Ltd. (1)(2)(3)
Date:08/14/2025
Viking Long Fund GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Long Fund GP LLC (1)(2)(3)
Date:08/14/2025
Viking Long Fund Master Ltd.
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Long Fund Master Ltd. (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Parent GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Portfolio GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Illiquid Investments Sub-Master LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Liquid Portfolio Sub-Master LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Liquid Portfolio Sub-Master LP (1)(2)(3)
Date:08/14/2025
HALVORSEN OLE ANDREAS
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of HALVORSEN OLE ANDREAS (1)
Date:08/14/2025
Ott David C.
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Ott David C. (2)
Date:08/14/2025
Shabet Rose Sharon
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Shabet Rose Sharon (3)
Date:08/14/2025
Comments accompanying signature:
(1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

FAQ

What stake in BridgeBio (BBIO) is reported by Viking Global Investors LP?

Viking Global Investors LP reports shared beneficial ownership of 17,780,183 shares, representing 9.3% of common stock based on 191,168,504 shares outstanding.

Which individuals are named as potentially having beneficial ownership?

The filing identifies O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet as Executive Committee members who may be deemed to have shared beneficial ownership of 18,602,920 shares (9.7%).

What source of funds was used for the reported purchases?

The source of funds for the purchases is stated as capital invested in the Funds by their investors.

Does the amendment report recent transactions in BridgeBio stock?

Except for transactions listed in Exhibit 99.8 to this Amendment No. 8, the Reporting Persons state they have not effected any transactions since Amendment No. 7 filed on July 1, 2025.

On what outstanding share count are the percentages based?

Percentages are calculated using 191,168,504 shares of common stock outstanding as of July 29, 2025.
Bridgebio Pharma

NASDAQ:BBIO

BBIO Rankings

BBIO Latest News

BBIO Latest SEC Filings

BBIO Stock Data

14.70B
166.55M
4.77%
101.53%
10.41%
Biotechnology
Pharmaceutical Preparations
Link
United States
PALO ALTO